SEC Form 4 · accession 0001593087-26-000011
CAPRICOR THERAPEUTICS, INC. · CAPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Bergmann
Officer — CHIEF FINANCIAL OFFICER
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001133869
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 22, 2026 | M | 500 | $3.18 | A | 11,723 | D | |
| Common Stock | Jun 22, 2026 | S | 500 | $30.00 | D | 11,223 | D | |
| Common Stock | Jun 24, 2026 | M | 400 | $3.18 | A | 11,623 | D | |
| Common Stock | Jun 24, 2026 | S | 400 | $30.00 | D | 11,223 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.18 | Jun 22, 2026 | M | 500 | D | — | Jan 3, 2032 | Common Stock | 500 | 116,480 | D |
| Stock Option (Right to Buy)F2 | $3.18 | Jun 24, 2026 | M | 400 | D | — | Jan 3, 2032 | Common Stock | 400 | 116,080 | D |
Explanation of responses
- F1Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2Shares vested 1/48th on the first day of each month commencing February 1, 2022.